A Randomized study of sofosbuvir plus ribavirin with and without PEG interferon alpha 2b in treatment of hepatitis C genotype 3 infection: Real life data from a Tertiary Care Center
DOI:
https://doi.org/10.7439/ijbar.v9i3.4673Keywords:
Consumption, antibacterial, appropriateness, respiratory tract infectionsAbstract
Background and Aim - Sofosbuvir, a polymerase inhibitor is pangenotypic directly acting antiviral for hepatitis C. In this study we evaluate two sofosbuvir containing regimens with or without pegylated interferon (PEGIFN) in patients with chronic hepatitis or compensated cirrhosis caused by hepatitis C genotype 3 infections. Methods - It was a prospective, single centre, randomized open label study. Thirty nine patients were randomized into two groups: sofosbuvir plus ribavirin with (A) and without (B) PEGIFN alpha 2b for 12 and 24 weeks respectively. Patients with contraindications and treatment experience were excluded. Primary end points were end of treatment response (ETR) and sustained virological response at 12 weeks (SVR12). Rates of adverse effects were secondary end point. Results- Baseline characteristics in both groups were comparable. Two patients in group B did not complete therapy and excluded from analysis. ETR and SVR12 rate in group A were 100 % and in group B were 89.4 % showing 100% concordance between ETR and SVR12 in either group. Non-specific adverse effects were more frequent in group A than group B (94.4 versus 79%). Rates of hemoglobin decrease, neutropenia and thrombocytopenia were 100, 17 and 44.4% in group A and 94, 0 and 15.8% in group B respectively. Conclusion- Addition of PEGIFN to sofosbuvir and ribavirin achieves higher ETR and SVR12 and reduces duration of therapy. PEG-IFN based treatment leads to higher hematological as well as non hematological side effects but these are mild and easily manageable during 12 weeks treatment.Downloads
References
Hatzakis A, Chulanov V, Gadano AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2. J Viral Hepat. 2015;22(suppl. S1):26–45.
Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology.2015;61:77–87.
Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.
Reyes-Mendez MA, Juarez-Figueroa L, Iracheta-Hernandez P, Medina-Islas Y, RuizGonzalez V. Comparison of two diagnostic algorithms for the identification of patients with HCV viremia using a new HCV antigen test. Ann Hepatol. 2014;13:337–342.
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.
Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.
Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa2a and ribavirin for non-cirrhotic, treatmentnaive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13:401–408.
Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatmentexperienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology. 2013;58:1380 A.
Esteban R, Nyberg L, Lalezari J, et al. Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy. J Hepatol. 2014;60:S4.
Bourlière M, Khaloun A, Wartelle- Bladou C, et al. Chronic hepatitis C: treatments of the future. Clin Res Hepatol Gastroenterol 2011;35:Suppl 2:S84-S95.
Lam AM, Murakami E, Espiritu C, et al. PSI-7851, a pronucleotide of beta-D-2′- deoxy-2′fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 2010;54: 3187-96.
Sofia MJ, Bao D, Chang W, et al. Discovery of a β-d-2’-deoxy-2′-α-fluoro-2′-β- Cmethyluridine nucleotide prodrug (PSI- 7977) for the treatment of hepatitis C virus. J Med Chem 2010;53:7202-18.
Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with HCV genotype 3 infection and treatment-experienced patients with cirrhosis and HCV genotype 2 infection. Gastroenterology. 2015. http://dx.doi.org/10.1053/j.gastro.2015.07.043.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
How to Cite
